NCT07214389 (PROMOTE-QI) is a NA clinical trial of Quality Measures (Audit and Feedback) in Opioid Use Disorder, sponsored by RTI International.

Who is sponsoring NCT07214389?

NCT07214389 is sponsored by RTI International.

What drugs are being tested in NCT07214389?

Interventions in NCT07214389: Quality Measures (Audit and Feedback), Quality Improvement (QI) Toolkit, External QI Facilitation.

What condition does NCT07214389 study?

NCT07214389 studies Opioid Use Disorder.

Is NCT07214389 still recruiting?

NCT07214389 is currently recruiting now. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT07214389: PROMOTE-QI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On: Project 2 - Producing Outcome Measures for OTP Quality Improvement

Recruiting now NA Last updated 16 April 2026

What this trial tests

NA trial testing Quality Measures (Audit and Feedback) in Opioid Use Disorder in 4,500 participants. Currently enrolling.

Timeline

3 October 2025

Primary endpoint
1 August 2027

1 December 2027

Quick facts

Lead sponsor	RTI International
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	4,500
Start date	3 October 2025
Primary completion	1 August 2027
Estimated completion	1 December 2027
Sites	1 location across United States

Drugs / interventions tested

Quality Measures (Audit and Feedback)
Quality Improvement (QI) Toolkit
External QI Facilitation

Conditions studied

Opioid Use Disorder — all drugs for Opioid Use Disorder →

Sponsor

RTI International — full company profile →

Who can join

18 and older, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

OTP's 90-day treatment retention rate
Time frame: 90 days after treatment initiation (episodes initiating within the 12 months after intervention launch)
The primary endpoint in the quantitative analyses will be the OTP's 90-day treatment retention rate.

Sponsor's own description

This study tests ways to help opioid treatment programs (OTPs) keep patients in care. Staying on methadone or buprenorphine is linked to better outcomes, yet many people leave treatment early. The project will compare two approaches that provide clinics with retention/outcome quality measures and a quality-improvement (QI) toolkit-either alone or with added facilitation-against usual care. Forty-five BayMark OTPs in multiple states will be randomly assigned to one of three groups: (1) quality measures + QI toolkit; (2) quality measures + QI toolkit + external QI facilitation; or (3) usual care. The primary outcome is 90-day retention in treatment, measured from OTP electronic health records and Medicaid claims. Secondary outcomes include emergency department visits, hospitalizations, overdoses, and mortality. Findings will identify practical, scalable strategies to improve patient retention in OTPs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Opioid Use Disorder

Currently open trials in the same condition.

NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting

Other RTI International trials

Trials by the same sponsor.

NCT07226401 — Virtual Village for Young Parents · NA · recruiting
NCT06778278 — Transition Health and Resilience Through Valued Experiences (THRiVE) Pilot for Newly Separated Veterans · NA · recruiting
NCT06927661 — ENSAND 2.0 Evaluation in Nigeria · NA · recruiting
NCT06927674 — DELIVER Evaluation in Nigeria · NA · recruiting
NCT05971888 — Better Dairy for All Evaluation in Ethiopia · NA · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07214389 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RTI International
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07214389.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing